Skip to main content

delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)

 

Following a full submission

AWMSG advice

Status: Recommended

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) is recommended as an option for use within NHS Wales as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

 Final Appraisal Recommendation (FAR): delta-9-tetrahydrocannabinol cannabidiol (Sativex) 644 (PDF, 260Kb)
 AWMSG Secretariat Appraisal Report (ASAR): delta-9-tetrahydrocannabinol cannabidiol (Sativex) 644 (PDF, 2.0Mb)

Medicine details

Medicine name delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)
Formulation 2.7 mg / 2.5mg oromucosal spray
Reference number 644
Indication

Treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy

Company Bayer Healthcare Pharmaceuticals
BNF chapter Musculoskeletal & joint diseases
Submission type Full
Status Recommended
Advice number 1814
NMG meeting date 18/06/2014
AWMSG meeting date 16/07/2014
Ratification by Welsh Government 13/08/2014
Date of issue 14/08/2014
Date of last review 31/10/2017